Abu Dhabi Islamic Bank : ADIB launches global Healthcare and Pharmaceuticals Equities Basket Note

• Bank's last three matured equity investment notes have yielded returns of 4.2%, 4.7% and 6.1%

UAE, Abu Dhabi, 01 May 2017 - Abu Dhabi Islamic Bank (ADIB), a leading financial institution, has launched a new Healthcare Pharmaceuticals Equities Basket Note designed to capitalize on projected growth in the healthcare industry. The Shariah-compliant note matures in 12 months and provides 100% capital protection at maturity to minimize investment risk. The note is currently open for subscription until 25 May 2017 and offers a 3-month lock-in period. The minimum investment for the note is US$30,000.

The product provides investors with exposure to a basket of leading international companies operating across the healthcare pharmaceutical sectors, including Celgene Corp, Merck & Co., Novartis AG, Novo Nordisk and Pfizer INC. Maturity date for the note is April 4, 2018, and return could reach up to 10.25%.

Daffer Luqman, Global Head of Liabilities and Wealth Management at ADIB, said: 'Global healthcare spend is projected to reach US$8.7 trillion by 2020 according to a recent Deloitte study. This note provides customers with exposure to leading international pharmaceutical companies with favorable growth prospects. Over the past couple of years, we have seen an increase in demand for notes that provide capital protection, such as ADIB's Shariah-compliant products. This new note is part of the bank's strategy to offer customers with wealth-tailored management solutions that address specific financial while maintaining a diversified investment portfolio.'

As one of the UAE's leading banks, ADIB continues to develop and deliver best-in-class solutions tailored to meet the financial needs of customers through effective financial planning and asset allocation.